Aim: To report on a descriptive survey on the availability, regulation and funding issues of assisted reproductive technology (ART) activities in member countries of the Asia and Oceania Federation of Obstetrics and Gynaecology (AOFOG). Methods: A survey questionnaire was initially sent out to representatives of the 28 member national societies of AOFOG in 2015, and final verification and compilation of data were completed in November 2017. Results: A response was received from 24 countries. Artificial insemination and in vitro fertilization treatments were available in 23 and 22 of them respectively. Of the 23 responding countries where ART activities were carried out, these were governed by legislation or national regulations in 12 of them, and 15 had a national registry, to which reporting was compulsory in 11 of them. Only Australia, Nepal, New Zealand and Saudi Arabia allowed ART treatment for both single men and women, while only Australia and New Zealand allowed ART treatment for homosexual couples. In Vietnam, ART treatment was allowed only for single women (but not men) from the same country. In Israel, only single or homosexual women but not men were allowed to receive ART treatment. Government subsidy was available for artificial insemination and in vitro fertilization treatments in 10 and 9 responding countries respectively. Compensation to gamete donors and surrogate mothers were allowed in some countries, mostly on the basis of covering the medical treatment cost and compensation for leave from work. Conclusion: There is great diversity in the availability of various forms of ART treatments, their regulations and data-monitoring mechanisms, as well as funding issues, among Asian-Oceanic countries. Availability of ART activities involving donor gametes or surrogacy, or those for nonheterosexual unions, is still limited in this region.
Introduction
In 1994, the first survey on the status of assisted reproductive technology (ART) in the Asian-Oceanic region was published by the Asia and Oceania Federation of Obstetrics and Gynaecology (AOFOG). 1 In this survey, 12 of the then 19 member nations of the AOFOG responded. Throughout the past two decades, there have been huge increases in the popularity and accessibility of ART worldwide, 2,3 as well as tremendous technical advances and changes in regulations in this very specialized field. In view of this, the Reproductive Endocrinology and Infertility Committee of AOFOG initiated another survey in 2015.
The data have been finally compiled in 2017 and are presented in this report. Despite nonresponse from five member countries, this report may serve as a useful descriptive record for our region, based on which further clinical developments and educational activities in the region can be planned.
Methods
The survey questionnaire was initially sent out to representatives of the 28 member national societies of AOFOG in April 2015. Due to incomplete data entries and nonresponse from some member countries, another exercise of data collection and verification was carried out in 2017 by the authors by contacting the original respondents or new contact persons in the respective countries. For the purpose of this report, ART activities include both artificial insemination and in vitro fertilization (IVF) with or without intracytoplasmic injection (ICSI).
Results
Responses were received from 24 out of the 28 member countries, including Australia, Bangladesh, 
Availability of national registry for ART activities
Of the 23 responding countries with ART activities, 15 have a national registry administered by the national health authority and/or a medical organization, to which reporting is compulsory in 11 of them ( Table 2 ).
Availability of treatment by ART outside heterosexual unions
Among the responding countries, only Australia, Nepal, New Zealand and Saudi Arabia allow ART treatment to be offered to both single men and women, while only Australia and New Zealand allow ART treatment for homosexual couples. In Israel, only single or homosexual women, but not men, are allowed to receive ART treatment. In Vietnam, only single women (but not men) from the same country are allowed to receive ART treatment (Table 3 ).
Cost and financial issues for ART treatment
The typical cost per treatment cycle of IVF was US $2500 or above in all responding countries, and that for AIH varied widely among the responding countries, from less than US$200 to more than US$2500. Government subsidy is available for IVF treatment in 9 responding countries and for AIH treatment in 10 responding countries (including Macau, where only AIH but not IVF activity is currently available) ( Table 4 ). Compensation to both gamete donors and surrogate mothers is permitted in Australia, India, Israel, Korea, Malaysia, Nepal and Sri Lanka. In Hong Kong and Taiwan, compensation to gamete donors but not surrogate mothers is permitted (Table 4 ). In most of these countries, compensation is permitted only on the basis of covering for the medical treatment cost and compensation for leave from work, except for India and Nepal, where additional monetary compensation to the donor or surrogate mother in addition to the above cost covering is permitted.
Discussion
This is an update on the status of ART activities in the Asia and Oceania region since the last report of this kind was published by AOFOG in 1994. Of 28 member nations, 24 responded in either or both of the data collection exercises conducted in 2015 and 2017. The authors tried their very best to make the data complete, although there were still a number of unanswered items in the returned survey questionnaire. Hence, in compiling this report, we selected the most important parameters where data were complete and verifiable, aiming at providing an overview of ART activities in this region to aid further regulatory developments and internation collaborations. Our results showed that treatment by ART, including IVF and AIH, is available in most responding countries, although the existence of official legislation or regulations on ART activities does vary and was present in 12 of the 23 (52.2%) responding countries where ART activities exist. This percentage is similar to the figure reported in the recent international surveillance report (57.1%) published by the International Federation of Fertility Societies (IFFS), and more and more countries are establishing such legislations and national regulations over the past few years. 3 In this recent IFFS survey, another 24.3% of responding countries had some guidelines established by professional bodies, and only 18.3% did not have any form of regulatory structure on ART activities. 3 Only 15 of the 23 (65.2%) responding countries with ART activities had a central national registry. Indeed, the presence of a central national registry would be important and essential for the provision of accurate audit data.
Great diversity was observed in the availability of third-party reproduction involving the use of donor gametes/embryos or surrogate mothers, or ART treatment outside heterosexual unions, with significant cultural and religious influences. Of note, only 14 of the 23 (60.9%) responding countries with ART activities allow some form of third-party ART procedures, and 6 of these 23 countries (26.1%) allow ART activities outside heterosexual unions in some way. Less than half (9 for IVF and 10 for AIH of 23) of the responding countries provide subsidy from the government in support of ART treatments, and even less so for treatment involving donor gametes or surrogacy (data not shown).
It was recognized that questions on the number of ART centers, caseload, success rate, pregnancy outcomes and complication rates, although being important information, are often difficult to be precisely and accurately estimated by individual respondents on behalf of their respective countries. This is particularly true for large countries with a huge number of ART centers and those where no central registry on ART activities exists, and hence, clinical data are only collected sporadically, if at all. The same problem was actually encountered in the international survey by IFFS. 3 Indeed, these data were not provided by most of the responding countries, and hence, it was decided that we do not report on these items, although they were included in the original questionnaire.
There is a plan that AOFOG will conduct this survey on a regular basis in future years. We are in the process of refining the survey questionnaire to reduce the complexity and ambiguity of the questions and to introduce mechanisms within the network to enhance data collection and verification. There have been emerging topics that have become increasingly important in the field of ART, for instance, issues on single embryo transfer policies, gender selection, fertility preservation and the posthumous use of stored gametes and embryos. Furthermore, as preimplantation genetic diagnosis and screening have become an increasingly important area in ART practice in the past decade, it is important to collect data on this as well. Certainly, these need to be included in the upcoming surveys.
With the increasing popularity of medical tourism in the region and people seeking cross-border ART treatment, such data would be important references to policymakers and regulatory bodies. The diversity among countries in the regulation and availability of various forms of ART treatments, especially those involving third-party reproduction or nonheterosexual unions or those involving newer techniques such as preimplantation genetic diagnosis or screening, would largely explain the phenomenon of reproductive tourism. Despite controversies from medical and ethical perspectives, this is unavoidable in the globalizing world. 4, 5 Data from Europe and America suggested that about 3-5% of ART activities carried out in recent years involved cross-border patients. [5] [6] [7] It is certainly worthwhile to look into such data in our region in future surveys.
In conclusion, we observed great diversity in the availability of various forms of ART treatments, their regulations and data-monitoring mechanisms, as well as funding issues, among Asian-Oceanic countries. The availability of ART activities involving donor gametes or surrogacy, or those for nonheterosexual unions, is still limited in this region.
